Pharma Industry - Most Connected
A list of the most connected companies in the pharmaceutical industry. A ranking of the top pharma companies based on how many business relationships their employees have and how strong those relationships are.
Never miss news on these companies! Never miss an update. Join Nudge.ai. Join Nudge.ai to get daily email updates on these companies, see your network's relationships at these companies and get warm intros. Get Started
Pharma Industry - Most Connected
A list of the most connected companies in the pharmaceutical industry. A ranking of the top pharma companies based on how many business relationships their employees have and how strong those relationships are.
Pfizer Canada Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives. We make medicines and vaccines that help people when they are sick and prevent them from getting sick in the first place, as well as some of the world’s best-known consumer healthcare brands. Every day, our colleagues work in developed and emerging markets to treat, cure and eradicate life-threatening conditions and challenge some of the most feared diseases of our time. Pfizer also collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, visit www.pfizer.com.
Merck Animal Health To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.
Novartis AG Novartis provides healthcare solutions that address the evolving needs of patients and societies worldwide. We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering, and to enhance the quality of life. Our portfolio focuses on broad areas of healthcare: pharmaceuticals, eye care, generic, vaccines, and over-the-counter medicines. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 135,000 associates and operate in more than 150 countries around the world. See our community guidelines: http://bit.ly/1wJeenJ
Amgen Inc. Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology, and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.
Baxter International Inc. Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2013 sales of $15.3 billion and has approximately 61,500 employees.
Takeda Oncology Takeda es una compañía farmacéutica global de investigación, con una fuerte presencia comercial en las áreas terapéuticas de enfermedades metabólicas, gastroenterología, oncología, cardiovascular, enfermedades del sistema nervioso central, enfermedades inflamatorias y del sistema inmunológico, respiratorio y dolor. Como la mayor compañía farmacéutica de Japón y una de las compañías líderes de la industria, Takeda dirige sus esfuerzos para mejorar la salud de los pacientes en todo el mundo a través de una innovación líder en el campo de la medicina. La compañía tiene presencia comercial en más de 70 países, con particular fortaleza en Ásia, Norteamérica, Europa y en mercados emergentes de rápido crecimiento como Latinoamérica, Rusia y China.
Novo Nordisk Canada Inc. At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Celgene Corporation Celgene is a multinational biopharmaceutical company committed to delivering truly innovative and life-changing therapies to improve the lives of patients worldwide. We are focused on the discovery, development, and commercialization of products for the treatment of cancer and inflammatory diseases through gene and protein regulation. Our talent, scientific knowledge and research capabilities help us to deliver access to innovative, disease-altering therapies to those who need them most. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies. Celgene Responsibility, which includes patient & communities, safety, governance, global health and environment, defines who we are and ensures that we continue to provide and to maximize opportunities for our patients, our partners, our employees and our planet. We are headquartered in Summit, New Jersey with over 6,600 employees located in more than 50 countries
Gilead Sciences The Gilead Code of Ethics requires employees' compliance with all laws and mandates fair dealing in all instances. Violations of our Code of Ethics by employees are not tolerated and can lead to disciplinary action, including termination of employment and referral for criminal prosecution. As part of our commitment to ensure our products are free from violations of all types of ethical standards, we plan to update our Code of Ethics and employee training materials to include provisions specifically targeted to address human slavery and trafficking.
Shire Pharma Shire is now part of Takeda. Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
Mylan Mylan is one of the world’s leading global pharmaceutical companies. Our medicines range from difficult-to-manufacture dosage forms, such as injectables and transdermal patches, to HIV/AIDS antiretroviral therapies, and include generic, brand and specialty products. The company has exceptional research and development capabilities and is one of the world’s largest active pharmaceutical ingredient manufacturers. Every one of Mylan’s 1,300-plus products meets one global quality standard regardless of where it is produced. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.
Astellas Pharma US, Inc. Astellas Pharma Inc. is primarily engaged in manufacturing, fabricating, or processing drugs in pharmaceutical preparations for human or veterinary use. The greater part of the products of these are finished in the form intended for final consumption, such as ampoules, tablets, capsules, vials, ointments, medicinal powders, solutions, and suspensions. Products of this industry consist of two important lines, namely: (1) pharmaceutical preparations promoted primarily to the dental, medical, or veterinary professions, and (2) pharmaceutical preparations promoted primarily to the public.
Merck KGaA, Darmstadt, Germany Merck is a global pharmaceutical and chemical company with total revenues of € 7.7 billion in 2009, a history that began in 1668, and a future shaped by around 33,600 employees in 64 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interests.
Alexion Pharmaceuticals Since its founding, Alexion has given hope to people who had none and shined a light on those who felt isolated and alone. But we know that fighting rare diseases takes so much more than hope. It requires persistence, dedication, and a relentless pursuit of the highest levels of medical innovation.
Zoetis Inc. Zoetis, formerly a business unit of Pfizer, is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on 60 years of experience, we deliver quality medicines and vaccines, complemented by diagnostics products and genetics tests and supported by a range of services. We are working every day to better understand and address the real-world challenges faced by those who raise and care for animals in ways they find truly relevant. Our name, Zoetis (zō-EH-tis), has its root in zo, familiar in words such as zoo and zoology and derived from zoetic, meaning “pertaining to life.” It signals our company’s dedication to supporting the veterinarians and livestock producers everywhere who raise and care for the farm and companion animals on which we all depend.
Alere Inc. Alere Wellbeing brings together science, technology, and personal interaction to help people recognize and modify unhealthy behaviors to avoid chronic illness and live longer, more vital lives. Alere Wellbeing’s evidence-based programs address modifiable health risks that contribute to chronic disease: tobacco use, poor nutrition, physical inactivity, and stress. Current clients include 27 state governments and more than 675 health plans and employers, 76 of which are in the Fortune 500. Alere Wellbeing is known and respected for its pay-for performance business model, intense focus on scalable service quality, dedicated account management, continuous program improvement, and transparent reporting of measurable outcomes at the individual participant and aggregate population level. Alere Wellbeing has contributed to more than 100 published research studies and maintains collaboration with the American Cancer Society® and an active research program funded by the Centers for Disease Contr
Lonza Group Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&B
MALLINCKRODT, INC. Mallinckrodt, Inc. is a global company serving selected healthcare markets with products used primarily for respiratory care, diagnostic imaging and pain relief. The Company manufactures and distributes advanced products for acute and chronic respiratory care, imaging products for disease diagnosis, and pharmaceutical products used in pain management. The Company is comprised of three business segments: Respiratory, Imaging and Pharmaceuticals.
Perrigo Company Perrigo Company plc, a top five global over-the-counter (OTC) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of branded OTC products, generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides “Quality Affordable Healthcare Products®” across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other key markets including Israel and China. Visit Perrigo online at (http://www.perrigo.com).
Mead Johnson Nutrition For more than a century, Mead Johnson Nutrition has led the way in developing products designed to help meet the nutritional needs of infants and children. Today, that passion remains our primary pursuit. Parents and healthcare professionals around the world trust Mead Johnson Nutrition to provide sustenance, strength and support to newborns, infants, and young children.
Valeant Pharmaceuticals International, Inc Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives throughout more than 100 countries. Valeant’s primary focus is in the areas of dermatology and eye health. Valeant has an established portfolio of durable products and our strategy is to focus the business on core geographies and therapeutic areas that offer high-growth opportunities. Another critical element of our strategy is business development. We have completed numerous transactions over the past few years, including the acquisition of international eye health organization Bausch + Lomb in 2013, to expand our portfolio and our geographic footprint. We will continue to pursue value-added business development opportunities as they arise. Valeant’s strategic markets are primarily in th
BorgWarner Inc. here are few challenges as important today as creating solutions that support a cleaner, more energy-efficient world. This requires a commitment to constantly improve the transportation of people and things. We, at BorgWarner, made that commitment decades ago and have since been creating technologies to improve efficiency, emissions and performance in all types of vehicles.
SUN PHARMA Sun Pharma is the world's fifth largest generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 2,000 scientists and R&D investments of over 7-8% of annual revenues.
Novozymes Novozymes is the world leader in bioinnovation. We work with our partners to innovate new solutions and rethink industries around the world. Our industrial enzymes, microorganisms, biopolymers and other proteins allow our customers to achieve more efficient use of raw materials, reduce energy consumption, replace traditional chemicals with more sustainable alternatives, and offer higher-quality products. We rethink everyday products every day.
Jazz Pharmaceuticals About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology.
Dr. Reddy's Laboratories - Bristol Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology
Hikma Pharmaceuticals Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa (MENA) and Europe. In the United States, Hikma operates through its wholly owned subsidiary, West-Ward Pharmaceuticals Corp., with operations based in New Jersey, Ohio and Tennessee.
Lupin Limited Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment. Lupin is the 6th largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 9th) and South Africa (ranked 4th - IMS Health). For the financial year ended 31st March 2016, Lupin's Consolidated turnover and Profit after Tax were Rs. 137,016 million (USD 2.09 billion) and Rs. 22,707 million (USD 347 million) respectively.
Santen At Santen, we’re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a globally competitive company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in Europe, Japan, and the United States. Santen World Wide http://www.santen.com/ Santen United States http://www.santeninc.com/ Santen Europe http://www.santen.eu/ Japan http://www.santen.co.jp/ Asia http://www.santen-china.oinsite.cn/
AstraZeneca Pharmaceuticals AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.
Fresenius At Fresenius, the patient always comes first. For more than 100 years now we have been working to save lives and improve the quality of life of our patients. A clear focus on innovation and efficiency has helped us to make high-quality healthcare accessible to a steadily increasing number of people. Yet we never get complacent about our successes, and never stop looking for better solutions. This is how Fresenius is contributing to medical progress and better patient care. At Fresenius, “Forward Thinking Healthcare” captures our commitment to the future: better medicine for more people.
STADA Arzneimittel AG STADA has its own sales companies in Vietnam named STADA - Vietnam J.V. Co., Ltd., Ho-Chi-Minh-City and Pymepharco Joint Stock Company, Tuy Hoa City. STADA Arzneimittel (Germany): was established in 1895. And now STADA AG is included in the list of MDAX with forty branches in twenty-seven different countries. All pharmaceutical products of STADA always observe the principles of WHO-GMP and Total Quality Management. M.S.T Pharmaceutical Co., Ltd: was established on January 25, 2000.
See who in your network can offer warm introductions to companies on this list With Nudge.ai you can instantly uncover which contacts on this company list your network is most strongly connected to and where your team has existing relationships.
Pharma Industry - Most Connected Recent News Mentions
bizwest.com Jun. 21, 2019
Array Acquisition Provides “Blockbuster Revenue Potential” For Pfizer – Bizwest
BOULDER — Array Biopharma Inc. (Nasdaq: ARRY) posted a net loss of $11.4 million in the second quarter of 2019, but that’s no cause for concern for Pfizer Inc. (NYSE: PFE). The pharmaceutical giant, which is buying Array for about $11 billion, is betting the Boulder-based cancer therapy developer has the potential to provide “blockbuster revenue potential” in the long term. “We have the rare opportunity to advance our oncology strategy and to augment our business with three value drivers,” said
businesswire.com Jun. 20, 2019
Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth And Focus On Innovative Research And Development
Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
americanbankingnews.com Jun. 18, 2019
Borgwarner Inc. (NYSE:BWA) Sees Large Growth In Short Interest
BorgWarner Inc. (NYSE:BWA) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 5,513,900 shares, a growth of 30.1% from the April 15th total of 4,238,000 shares. Based on an average daily volume of 1,580,000 shares, the short-interest ratio is presently 3.5 days. Currently, […]
businesswire.com Jun. 17, 2019
Novo Nordisk Canada Joins Biotalent Canada National Partnership Network
BioTalent Canada today announced Novo Nordisk Canada Inc. has joined its national Partnership Plus network.
americanbankingnews.com Jun. 14, 2019
Hansberger Growth Investors LP Has $2.20 Million Position In GRIFOLS S A/S (NASDAQ:GRFS)
Hansberger Growth Investors LP increased its holdings in GRIFOLS S A/S (NASDAQ:GRFS) by 5.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 109,327 shares of the biotechnology company’s stock after purchasing an additional 5,402 shares during the quarter. GRIFOLS S A/S accounts for about […]
zacks.com Jun. 12, 2019
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year? - June 12, 2019
Is (GILD) Outperforming Other Medical Stocks This Year?
wsj.com Jun. 5, 2019
Bristol R&D Chief To Leave After Celgene Acquisition
Bristol-Myers Squibb’s research-and-development chief will leave the company later this year after the drugmaker completes its $74 billion acquisition of rival Celgene.
fiercebiotech.com May. 29, 2019
Inovio Shares Fall As Astrazeneca Pares Down Partnership
As the dust settles on a continued exodus at AstraZeneca and faces and units are replaced, it seems the U.K.-based Big Pharma is starting to look at cutting some of the fat from its external pacts, and Inovio Pharmaceuticals is in the crosshairs.
Save time on prospect research. Nudge.ai automatically gives you insights and updates on the accounts you care about.Start 30-day free trial Learn More
Save time on prospect research. Nudge.ai automatically gives you insights and updates on the accounts you care about.See your relationships